# A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in Participants With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors (P02173)

> **NCT03882905** · PHASE3 · COMPLETED · sponsor: **Organon and Co** · enrollment: 769 (actual)

## Conditions studied

- Primary Hypercholesterolemia

## Interventions

- **DRUG:** Ezetimibe
- **DRUG:** Placebo
- **DRUG:** Simivastatin
- **DRUG:** Statin

## Key facts

- **NCT ID:** NCT03882905
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-01-31
- **Primary completion:** 2001-07-27
- **Final completion:** 2001-07-27
- **Target enrollment:** 769 (ACTUAL)
- **Last updated:** 2024-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03882905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03882905, "A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in Participants With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors (P02173)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03882905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*